Growth hormone trial for CF wasting halted early
NCT ID NCT00803179
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small Phase 1 trial tested growth hormone in 5 adults with cystic fibrosis who were underweight. The goal was to see if the hormone could help them gain weight and muscle, improve their quality of life, and monitor effects on lung function and diabetes. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Growth hormone (somatropin)
- What this could lead to
- If it works, this could point toward a treatment to help people with cystic fibrosis gain weight and improve their quality of life.
- What could go wrong
- This is a very early, tiny trial (only 5 participants) that was terminated, so results are limited. Growth hormone may also affect blood sugar and diabetes risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Umms/Ummhc
Worcester, Massachusetts, 01655, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smartphone tool may help cystic fibrosis patients survive the lung transplant waitlist
- Can a smartphone app reveal how CF treatments really work at home?
- Can a peer coach help young people take control of their chronic illness?
- Could a single antibiotic be enough for cystic fibrosis lung infections?
- Early use of powerful CF drugs may boost growth in young children
- Hands-On therapy may soothe cystic fibrosis pain without drugs